DOCSLIB.ORG

18Th Meeting of the European Venous Forum 29 June - 1 July, 2017 Porto, Portugal

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
18Th Meeting of the European Venous Forum 29 June - 1 July, 2017 Porto, Portugal 18th Meeting of the European Venous Forum 29 June - 1 July, 2017 Porto, Portugal Alfaˆ��n����������ega Porto �ongre������ss� �������enter, Porto, Portugal SCIENTIFIC PROGRAMME AND BOOK OF ABSTRACTS EDIZIONI MINERVA MEDIca Under the auspices of: International Union of Angiology Union Internationale �e Phlébologie – International Union of Phlebology Senior Corporate Members The European Venou� Forum i� extremely grateful to the following companie� for their continue� generou� �upport Senior Corporate Members BSN me�ical Me�tronic SERVIER SIGVARIS Management AG Corporate Members Kreussler Pharma Pierre Fabre © 2017 – EDIZIONI MINERVA MEDICA S.p.A. – �or�o Bramante 83/85 – 10126 Torino Web �ite: www.minervame�ica.it / e-mail: minervame�ica@minervame�ica.it All right� re�erve�. No part of thi� publication may be repro�uce�, �tore� in retrieval �y�tem, or tran�mitte� in any form or by any mean�. CONTENTS Welcome me��age …………………………………………………………………………………………………………… IV �ommittee� ………………………………………………………………………………………………………………………… V Foun�er Member� …………………………………………………………………………………………………………… IX �ongre�� Information …………………………………………………………………………………………………… XIII Scientific Programme Information …………………………………………………………………………… XVI Scientific Programme ………………………………………………………………………………………………… XVII Thursday 29 June 2017 …………………………………………………………………………………………… XVII Fri�ay 30 June 2017 ………………………………………………………………………………………………… XIX Satur�ay 1 July 2017 ……………………………………………………………………………………………… XXII Electronic Presentations ………………………………………………………………………………………… XXV Industry Sponsored Symposia ………………………………………………………………………………… XXXI Exhibition Companies …………………………………………………………………………………………… XXXII Exhibition Plan …………………………………………………………………………………………………… XXXIII Book of Abstracts ……………………………………………………………………………………………………………… 1 Author Index ………………………………………………………………………………………………………………… 107 IV WELCOME MESSAGE Welcome to EVF Porto 2017! The European Venou� Forum Annual Meeting 2017 i� hel� in the city of Porto between June 29th an� July 1�t. The venue will be the Alfân�ega �ongress �entre that wa� recently vote� Europe’� Be�t Meeting� �onference �entre �uring the Bu�iness De�tination� Travel Awards in 2014 an� 2015. The scientific programme will provide participants with a three-day conference on the most up to date infor- mation about new �evelopment� in clinical practice an� relevant re�earch. Important up�ate� an� re-evalu- ation� of the late�t technologie� an� technique�, �iagno�tic mo�alitie�, an� �ata from clinical trial� will be pre�ente� an� �i�cusse�. The panel of expert international �peaker� will pre�ent thi� cutting-e�ge information a� well a� being avail- able for your comment� an� querie�. The target au�ience will be mo�tly Va�cular Surgeon� an� Re�i�ent� but al�o Angiology Speciali�t�, Phlebo- logi�t�, Interventional Ra�iologi�t�, Va�cular Me�icine Speciali�t�, Nur�e�, Technician� an� all other� inter- e�te� in the management of venou� �i�ea�e. As always your participation will be crucial! The EVF is your Society and we need the scientific input of all member�. The centerpiece of our �aily �ession� will be the peer-reviewe� pre�entation� �electe� from the be�t of the �ubmitte� ab�tract�. We welcome you to Porto and hope that you will enjoy the final scientific programme. Armando Mansilha EVF Pre�i�ent an� Local �hairman V COMMITTEES CONGRESS PRESIDENT Prof Arman�o Man�ilha, Pre�i�ent, European Venou� Forum SCIENTIFIC COMMITTEE / LOCAL ORGANISING COMMITTEE Niel� Baekgaar� (Denmark) An�rew Bra�bury (UK) Athana�io� Giannouka� (Greece) Arman�o Man�ilha (Portugal) Michel Perrin (France) An�rew Nicolai�e� (�ypru�) Pavel Pore�o� (Slovenia) EVF EXECUTIVE COMMITTEE President: Professor Arman�o Man�ilha (Portugal) President Elect (1st): Professor Athana�io� Giannouka� (Greece) President Elect (2nd): Dr Dominik Heim (Switzerlan�) Secretary: Professor Athana�io� Giannouka� (Greece) Treasurer: Dr Marianne Van�en�riessche (Belgium) Assistant Treasurer: Dr Oscar Maleti (Italy) Chairman of the Board: Professor An�rew Nicolai�e� (�ypru�) IMMEDIATE PAST PRESIDENT Professor An�rew Bra�bury (UK) HONORARY MEMBERS Professor Eliete Bou�kela (Brazil) Professor Mark Malouf (Au�tralia) Professor Joe �aprini (USA) Professor Robert McLafferty (USA) Professor Anthony �omerota (USA) Professor Peter Neglen (�ypru�) Professor Bo Eklöf (Swe�en) Mr Kypro� Nichola� (UK) Professor Jawe� Faree� (USA) Professor Se�ha�ri Raju (USA) Professor Peter Gloviczki (USA) Professor Norman Rich (USA) Professor Roger Greenhalgh (UK) Professor Michel Samama (France) Dr John Hobb� (UK) Dr William San�mann (Germany) Professor Russel Hull (�ana�a) Professor Yuri Stokyo (Russia) Professor Lowell Kabnick (USA) Professor An�re van Rij (New Zealan�) Professor Robert Ki�tner (USA) Dr Thomas Wakefield (USA) Professor Dino� Lazari�e� (Greece) Dr Zivan Mak�imovic (Serbia) Professor Fe�or Lurie (USA) VI DATE FOR YOUR DIARY! 8th EVF HOW - Hands-on Work�hop on Venou� Di�ea�e Krakow, Polan�, 26-28 October 2017 www.evfvip.com 19th meeting of the European Venou� Forum Athen�, Greece, 28-30 June, 2018 un�er the Pre�i�ency of Professor Athana�io� Giannouka� ANNUAL MEETINGS/PAST PRESIDENTS Inaugural Meeting, 29 June – 1 July 2000 Lyon, France Michel Perrin 2n� Meeting, 13-14 September 2001 Rome, Italy �lau�io Allegra 3r� Meeting, 14-16 June 2002 Berlin, Germany Ulrich Schultz-Ehrenburg 4th Meeting, 27-29 June 2003 Li�bon, Portugal Jo�e Fernan�e� e Fernan�e� 5th Meeting, 25-27 June 2004 War�aw, Polan� Arka�iu�z Jawien 6th Meeting, 24-26 June 2005 �rete, Greece A�terio� Kat�amouri� 7th Meeting, 29 June-1 July 2006 Lon�on, UK Alun Davie� 8th Meeting, 29 June-1 July 2007 Istanbul, Turkey Mehmet Kurtoglu 9th Meeting, 26-28 June 2008 Barcelona, Spain Marc �airol� 10th Meeting, 5-7 June 2009 �openhagen, Denmark Neil� Baekgaar� 11th Meeting, 24-26 June 2010 Antwerp, Belgium Marianne DeMae�eneer 12th Meeting, 30 June-3 July 2011 Ljubljana, Slovenia Pavel Pore�o� 13th Meeting, 28-30 June 2012 Florence, Italy Giovanni Mo�ti 14th Meeting, 27-30 June 2013 Belgra�e, Serbia Dragan Milic 15th Meeting, 26-28 June 2014 Pari�, France Jean-Luc Gillet 16th Meeting, 2-4 July 2015 St Peter�burg, Russia Evgeny Shay�akov 17th Meeting, 7-9 July 2016 Lon�on, UK An�rew Bra�bury EUROPEAN VENOUS FOUNDATION The European Venou� Foun�ation, a UK regi�tere� charity (number 1100372) ha� been e�tabli�he� to pro- mote re�earch into the cau�e�, effect�, treatment an� management of venou� �i�ea�e an� to �upport the work of the European Venous Forum. Further details can be found from the EVF Office. TRUSTEES An�rew Nicolai�e� Michel Perrin Arka�iu�z Jawien Marianne Van�en�riessche Kypro� Nichola� Anne Taft CONTACT Anne Taft, MSc Dawn Bon�, MA European Venou� Forum PO Box 172, Greenfor�, Middx, UB6 9ZN (UK) Tel/Fax: +44 (0)20 8575 7044 E.mail: a�min@europeanvenou�forum.org exhibition@europeanvenou�forum.org IX FOUNDER MEMBERS Mohamma� Abu-Baker (Romania) Norbert Fring� (Germany) Ingri� Achhammer (France) Jury Fritz�che (Switzerlan�) Obiekezie Agu (UK) Alessan�ro Frullini (Italy) Efthimio� Alamano� (Greece) Jo�e Antonio Pereira Albino (Portugal) Diego Garce� (France) Joao Albuquerque R �a�tro (Portugal) �lau�e Gar�e (France) �lau�io Allegra (Italy) Michael Georgiev (Italy) Zacharia� An�roulaki� (Greece) George Geroulako� (UK) Jecu Avram (Romania) Joao Paulo Azeve�o Lope� �o� Santo� (Portugal) Athana�io� Giannouka� (Greece) Enrique Ginzburg (USA) Paul Bachoo (UK) Teimuraz Gogola�ze (Georgia) Giovani Ban�iera (Italy) Sue Goldsborough (UK ) Arie Bass (Israel) Joerg Dieter Gruss (Germany) Pietro Bavera (Italy) Jean-Jerome Guex (France) Gianni Belcaro (Italy) �leu�a Ema Belczak (Brazil) Epaminon�a� Helmi� (Greece) Jean-Patrick Benigni (France) Tet�uya Hirano (Japan) Antony Bertran� (Belgium) Mo Howla�er (UK) Imre Bihari (Hungary) Piero Bona�eo (Italy) �hri�to� Ioannou (Greece) �arlo� Bone (Spain) E�mon�o Ippolito (Italy) An�rew Bra�bury (UK) Takehi�a Iwai (Japan) Stephen Brook� (UK) Mark Iwanicki (USA) George� Buchheim (Switzerlan�) Maria Iwanicki (USA) �lare Butler (UK) George� Jantet (France) Juan �abrera (Spain) Arka�iu�z Jawien (Polan�) Alberto �aggiati (Italy) Mae�o Lebrun Jor�i (Spain) Marc �airol� (Spain) �lau�e Juhan (France) Jo�eph �aprini (USA) Eric Janin (France) Pe�ro �a�tell� (Spain) Mariella �atalano (Italy) Alexan�ro� Kafetzaki� (Greece) Attilio �avezzi (Italy) Marina Kafeza (Greece) Timothy �heatle (UK ) Michael Kai�er (Germany) Philip �oleri�ge-Smith (UK) Stavro� Kakko� (UK) �arlo� �o�ta �e Almei�a (Portugal) Evi Kalo�iki (UK) An�rew �ourt (UK) Yuk-Man Kan (UK) Deni� �reton (France) Dimitri� Kar�oula� (Greece) Svatopluk Ka�par (�zech Republic) Mario� Da�kalopoulo� (Greece) A�terio� Kat�amouri� (Greece) Stella Da�kalopoulou (Greece) Kon�tan�ino� Kat�eni� (Greece) Alun Davie� (UK) Holger Kie�ewetter (Germany) Marianne De Mae�eneer (Belgium) Shaukat Khan (UK) Howar� E Denbo (USA) Monica Kjaer (Denmark) Bogu�law Kompf (Polan�) Nichola� Fassia�i� (UK) Theo�oro� Ko�ta� (Greece) Jo�e Fernan�e� e Fernan�e� (Portugal) Kurt Kroeger (Germany) Philip Lag Francoi� (Belgium) Panteli� Kyprianou (�ypru�) X Peter Laba� (Slovak Republic) Bozina Ra�evic (Montenegro) Nico� Labropoulo� (USA) Albert-A�rien Ramelet (Switzerlan�) Zaza Lazara�hvili (Georgia) Stefano Ricci (Italy) Javier Leal-Mone�ero (Spain) Vaughan Ruckley (UK) �hri�tian Lebar� (France) Zbigniew Rybak (Polan�) Bb Lee (Korea) Marc Lefebvre-Vilar�ebo (France) Sergey Sapelkin (Russia) Rho�a Mackenzie (UK) Gerhar� Sattler (Germany) �a�tor Ma�uro-Maytin (Venezula) Michel Scha�eck (France) Grzegorz Ma�ycki (Polan�) Sanja Schuller-Petrovic
Load more

Recommended publications
  • Malta Medicines List April 08
    Defined Daily Doses Pharmacological Dispensing Active Ingredients Trade Name Dosage strength Dosage form ATC Code Comments (WHO) Classification Class Glucobay 50 50mg Alpha Glucosidase Inhibitor - Blood Acarbose Tablet 300mg A10BF01 PoM Glucose Lowering Glucobay 100 100mg Medicine Rantudil® Forte 60mg Capsule hard Anti-inflammatory and Acemetacine 0.12g anti rheumatic, non M01AB11 PoM steroidal Rantudil® Retard 90mg Slow release capsule Carbonic Anhydrase Inhibitor - Acetazolamide Diamox 250mg Tablet 750mg S01EC01 PoM Antiglaucoma Preparation Parasympatho- Powder and solvent for solution for mimetic - Acetylcholine Chloride Miovisin® 10mg/ml Refer to PIL S01EB09 PoM eye irrigation Antiglaucoma Preparation Acetylcysteine 200mg/ml Concentrate for solution for Acetylcysteine 200mg/ml Refer to PIL Antidote PoM Injection injection V03AB23 Zovirax™ Suspension 200mg/5ml Oral suspension Aciclovir Medovir 200 200mg Tablet Virucid 200 Zovirax® 200mg Dispersible film-coated tablets 4g Antiviral J05AB01 PoM Zovirax® 800mg Aciclovir Medovir 800 800mg Tablet Aciclovir Virucid 800 Virucid 400 400mg Tablet Aciclovir Merck 250mg Powder for solution for inj Immunovir® Zovirax® Cream PoM PoM Numark Cold Sore Cream 5% w/w (5g/100g)Cream Refer to PIL Antiviral D06BB03 Vitasorb Cold Sore OTC Cream Medovir PoM Neotigason® 10mg Acitretin Capsule 35mg Retinoid - Antipsoriatic D05BB02 PoM Neotigason® 25mg Acrivastine Benadryl® Allergy Relief 8mg Capsule 24mg Antihistamine R06AX18 OTC Carbomix 81.3%w/w Granules for oral suspension Antidiarrhoeal and Activated Charcoal
    [Show full text]
  • Product Monograph
    PRODUCT MONOGRAPH Sitcom LD Cream Each g contains : Euphorbia Prostrata Extract 1.0% w/w 10 mg (containing 0.315–0.825 mg total flavonoids calculated as apigenin-7-glucoside and 1.26–4.4 mg total phenolics calculated as gallic acid) and Lidocaine 3 % w/w 30 mg cream base. Cream Treatment of Haemorrhoids Manufactured By: Date of Preparation: The Madras Pharmaceuticals (05/07/2019) Old Mahabalipuram Road Karapakkam, Chennai Marketed By: Panacea Biotec Ltd. New Delhi 1 PART I: HEALTH PROFESSIONAL Page No. INFORMATION SUMMARY PRODUCT INFORMATION 4 INDICATIONS AND CLINICAL USE 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5 ADVERSE REACTIONS 7 DRUG INTERACTIONS 8 DOSAGE AND ADMINISTRATION 8 OVERDOSAGE 9 ACTION AND CLINICAL PHARMACOLOGY 9 STORAGE AND STABILITY 9 DOSAGE FORMS, COMPOSITION AND PACKAGING 9 PART II: SCIENTIFIC INFORMATION PHARMACEUTICAL INFORMATION 10 PART III: PATIENT INFORMATION 11 2 Sitcom LD Cream Each g contains : Euphorbia Prostrata Extract 1.0% w/w 10 mg (containing 0.315–0.825 mg total flavonoids calculated as apigenin-7-glucoside and 1.26–4.4 mg total phenolics calculated as gallic acid) and Lidocaine 3 % w/w 30 mg cream base. Cream Treatment of Haemorrhoids 3 PART I: HEALTH PROFESSIONAL INFORMATION SUMMARY PRODUCT INFORMATION Route of Dosage Form / Approved Indications Administration Strength Topical Sitcom LD Cream Euphorbia Prostrata is Euphorbia Prostrata indicated for: Extract 1.0% w/w 10 mg (containing 0.315–0.825 - Treatment of Bleeding mg total flavonoids Haemorrhoids calculated as apigenin- - In post- 7-glucoside and 1.26–4.4 haemorrhoidectomy. mg total phenolics calculated as gallic acid) and Lidocaine 3 % w/w 30 mg cream base.
    [Show full text]
  • Download This Issue
    UIP Chapter Meeting - August 25th -27th 2019, Krakow – Poland Contents Foreword 83 UIP Chapter Meeting August 25th -27th 2019, Krakow – Poland 85 Charing Cross International Symposium - Vascular & Endovascular Challenges Update April 15th-18th 2019, London – UK 191 81 Vol 26. No. 3. 2019 Medical Reporters’ Academy The reports from the UIP chapter meeting and Charing cross international symposium were prepared by the following members of the Medical Reporters’ Academy: Roman BREDIKHIN (Russia) Kirill LOBASTOV (Russia) Daniela MASTROIACOVO (Italy) Mustafa SIRLAK (Turkey) Stanislava TZANEVA (Austria) and chaired by: Andrew NICOLAIDES (Cyprus) 82 UIP Chapter Meeting - August 25th -27th 2019, Krakow – Poland Foreword The Medical Reporters’ Academy was co-founded in 1994 as a joint initiative by clinical and research venous disease specialists and Servier; with the main objective to develop an international group of young specialists with a core interest in venous disease drawn from various fields including dermatology, vascular surgery, angiology and/or phlebology. Each year the Medical Reporters’ Academy members are invited by Servier, to cover one of the most important international congresses for venous disease specialists. This year, the UIP Chapter Meeting, which was held in Krakow, Poland on August 25th- 27th, 2019 and the Charing Cross International Symposium: Vascular & Endovascular Challenges Update which was held in London, United Kingdom on April 15th - 18th, 2019 were selected because these congresses involved renowned international and national venous experts and young health care professionals providing a great opportunity to exchange ideas, explore strategies for vein care and discuss the latest trends & innovations in the field. Together with Andrew Nicolaides, the chairman of the group, the academy members explored the program of the congress, selected the events and presentations likely to present breakthroughs or new findings to attend, and wrote short reports.
    [Show full text]
  • DATA SUPPLEMENT Safety and Efficacy of Combination Nivolumab
    DATA SUPPLEMENT Safety and Efficacy of Combination Nivolumab Plus Ipilimumab in Patients with Advanced Melanoma: Results from a North American Expanded Access Program (CheckMate 218) F. Stephen Hodi, Paul B. Chapman, Mario Sznol, Christopher D. Lao, Rene Gonzalez, Michael Smylie, Gregory A. Daniels, John A. Thompson, Ragini Kudchadkar, William Sharfman, Michael Atkins, David R. Spigel, Anna Pavlick, Jose Monzon, Kevin B. Kim, Scott Ernst, Nikhil I. Khushalani, Wim van Dijck, Maurice Lobo, David Hogg 1 Supplementary Tables Table S1: Summary of adverse events reported between first dose and 30 days after last dose of the EAP therapy that required immune modulating medications in ≥1% of patients Nivolumab plus ipilimumab (N=754) Any grade, Grade 3–4, N (%)a N (%) Any adverse event 600 (80) 332 (44) Diarrhea 132 (18) 52 (7) Maculopapular rash 115 (15) 22 (3) Colitis 76 (10) 57 (8) Increased alanine aminotransferase 72 (10) 47 (6) Increased aspartate aminotransferase 58 (8) 32 (4) Rash 52 (7) 3 (<1) Pruritus 47 (6) 3 (<1) Pneumonitis 39 (5) 9 (1) Hypophysitis 38 (5) 5 (1) Autoimmune hepatitis 37 (5) 28 (4) Pruritic rash 29 (4) 0 Generalized pruritus 22 (3) 3 (<1) Nausea 20 (3) 5 (1) Adrenal insufficiency 18 (2) 3 (<1) Generalized rash 15 (2) 5 (1) Fatigue 14 (2) 3 (<1) Malignant neoplasm progression 12 (2) 11 (1) Arthralgia 12 (2) 2 (<1) Vomiting 12 (2) 2 (<1) Uveitis 11 (1) 1 (<1) Headache 11 (1) 1 (<1) increased transaminases 11 (1) 8 (1) Macular rash 11 (1) 2 (<1) Pyrexia 10 (1) 1 (<1) Increased lipase 10 (1) 9 (1) Acute kidney injury 9 (1) 6 (1) Hepatitis 9 (1) 6 (1) Cough 9 (1) 0 Acneiform dermatitis 9 (1) 0 Abdominal pain 8 (1) 2 (<1) aOne grade 5 adverse event (due to malignant neoplasm progression) was reported.
    [Show full text]
  • Malta Medicines List 25 7 07
    Defined Daily Doses Pharmacological Dispensing Active Ingredients Trade Name Dosage strength Dosage form ATC Code Comments (WHO) Classification Class Glucobay 50 50mg Alpha Glucosidase Inhibitor - Blood Acarbose Tablet 300mg A10BF01 PoM Glucose Lowering Glucobay 100 100mg Medicine Carbonic Anhydrase Inhibitor - Acetazolamide Diamox 250mg Tablet 750mg S01EC01 PoM Antiglaucoma Preparation Parasympatho- Powder and solvent for solution for mimetic - Acetylcholine Chloride Miovisin® 10mg/ml Refer to PIL S01EB09 PoM eye irrigation Antiglaucoma Preparation Zovirax™ Suspension 200mg/5ml Oral suspension Medovir 200 200mg Tablet Virucid 200 Zovirax® 200mg Dispersible film-coated tablets 4gAntiviral J05AB01 PoM Zovirax® 800mg Aciclovir Aciclovir Medovir 800 800mg Tablet Virucid 800 Virucid 400 400mg Tablet Zovirax® Cream 5% w/w Cream Refer to PIL Antiviral D06BB03 PoM Medovir Zovirax® Eye Ointment 3% w/w Eye ointment Refer to PIL Antiviral S01AD03 PoM Neotigason® 10mg Retinoid - Acitretin Capsule 35mg D05BB02 PoM Neotigason® 25mg Antipsoriatic Acrivastine Benadryl® Allergy Relief 8mg Capsule 24mg Antihistamine R06AX18 OTC Antidiarrhoeal and Activated Charcoal Biocarbon® 0.25g Tablet 5g A07BA01 OTC Antiflatulent Dentinox® Infant Colic 42mg/ml Oral suspension Drops Antifoaming agent - Activated Dimethicone Aero-OM® 100mg/ml Oral drops emulsion Refer to PILPreparation for colic A02X OTC or wind pain Aero-OM® 40mg Tablet Activated dimeticone, Antacid and Asilone Antacid Tablets 270mg 500mg Tablet Refer to PIL A02AB10 OTC Dried aluminium hydroxide Antiflatulent
    [Show full text]
  • Novel Therapies for Treating Diabetic Retinopathy
    International Journal of Molecular Sciences Review Moving Past Anti-VEGF: Novel Therapies for Treating Diabetic Retinopathy Mark T. Bolinger and David A. Antonetti * Departments of Ophthalmology and Visual Sciences, Kellogg Eye Center, and Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI 48105, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-734-232-8230 Academic Editor: Lu Cai Received: 20 June 2016; Accepted: 30 August 2016; Published: 7 September 2016 Abstract: Diabetic retinopathy is the leading cause of blindness in working age adults, and is projected to be a significant future health concern due to the rising incidence of diabetes. The recent advent of anti-vascular endothelial growth factor (VEGF) antibodies has revolutionized the treatment of diabetic retinopathy but a significant subset of patients fail to respond to treatment. Accumulating evidence indicates that inflammatory cytokines and chemokines other than VEGF may contribute to the disease process. The current review examines the presence of non-VEGF cytokines in the eyes of patients with diabetic retinopathy and highlights mechanistic pathways in relevant animal models. Finally, novel drug targets including components of the kinin–kallikrein system and emerging treatments such as anti-HPTP (human protein tyrosine phosphatase) β antibodies are discussed. Recognition of non-VEGF contributions to disease pathogenesis may lead to novel therapeutics to enhance existing treatments for patients who do not respond to anti-VEGF therapies. Keywords: diabetic retinopathy; diabetic macular edema; cytokine; VEGF; TNF-α; blood retinal barrier; corticosteroid; renin-angiotensin system; kinin-kallikrein system; angiopoietin; vitreomacular adhesion 1. Introduction Diabetic retinopathy (DR) is a serious threat to vision that is poised to become even more problematic with the increasing worldwide incidence of diabetes.
    [Show full text]
  • Anaesthetic Antacids: a Review of Its Pharmacological Properties and Therapeutic Efficacy
    International Journal of Research in Medical Sciences Parakh RK et al. Int J Res Med Sci. 2018 Feb;6(2):383-393 www.msjonline.org pISSN 2320-6071 | eISSN 2320-6012 DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20180005 Review Article Anaesthetic antacids: a review of its pharmacological properties and therapeutic efficacy Rajendra Kumar Parakh*, Neelakanth S. Patil Department of Medicine, SDM College of Medical Sciences and Hospital, Sattur, Dharwad, Karnataka, India Received: 13 December 2017 Accepted: 27 December 2017 *Correspondence: Dr. Rajendra Kumar Parakh, E-mail: [email protected] Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Anaesthetic antacids, combination of antacids (Aluminium hydroxide, Magnesium hydroxide) with an anaesthetic (oxethazaine), is becoming a choice of physicians and is re-emerging across all types of GI disorders (esophagitis, peptic ulcer, duodenal ulcer, heartburn, gastritis, functional dyspepsia), despite the discovery of potent and efficacious acid suppressants like H2 receptor blockers and proton pump inhibitors (PPIs). The reason being that anaesthetic antacids increase the gastric pH and provide relief from pain for a longer period of duration at considerably a lower dosage. Furthermore, it significantly increases the duration between the time of medication and the peak pH as compared to antacid alone. Oxethazaine, an anaesthetic component, produces a reversible loss of sensation and provides a prompt and prolonged relief of pain, thereby broadening the therapeutic spectrum of antacids.
    [Show full text]
  • Cardiovascular System Drug Poster
    Cardiovascular Drugs Created by the Njardarson Group (The University of Arizona): Edon Vitaku, Elizabeth A. Ilardi, Daniel J. Mack, Monica A. Fallon, Erik B. Gerlach, Miyant’e Y. Newton, Angela N. Yazzie, Jón T. Njarðarson Ethanol Glyceryl Trinitrate Anestisine Quinidine Procaine Adrenaline Adenosine Phenylepherine Heparin Vasoxyl Sotradecol Xylocaine Pronestyl Betamethasone Catapres Cedilanide Dopamine Inversine Metaraminol Acetyldigitoxin Hydrocortisone ( Ethanol ) ( Nitroglycerin ) ( Benzocaine ) ( Quinidine ) ( Procaine ) ( Epinephrine ) ( Adenosine ) ( Phenylephrine ) ( Heparin ) ( Methoxamine ) ( Sodium Tetradecyl Sulfate ) ( Lidocaine ) ( Procainamide ) ( Betamethasone ) ( Clonidine ) ( Deslanoside ) ( Dopamine ) ( Mecamylamine ) ( Metaraminol ) ( Acetyldigitoxin ) ( Hydrocortisone ) VASOPROTECTIVE CARDIAC THERAPY VASOPROTECTIVE CARDIAC THERAPY VASOPROTECTIVE CARDIAC THERAPY CARDIAC THERAPY CARDIAC THERAPY VASOPROTECTIVE CARDIAC THERAPY VASOPROTECTIVE CARDIAC THERAPY CARDIAC THERAPY VASOPROTECTIVE ANTIHYPERTENSIVE CARDIAC THERAPY CARDIAC THERAPY ANTIHYPERTENSIVE CARDIAC THERAPY CARDIAC THERAPY VASOPROTECTIVE Approved 1700s Approved 1879 Approved 1890s Approved 1900s Approved 1903 Approved 1920s Approved 1929 Approved 1930s Approved 1935 Approved 1940s Approved 1946 Approved 1949 Approved 1950 Approved 1950s Approved 1950s Approved 1950s Approved 1950s Approved 1950s Approved 1951 Approved 1952 Approved 1952 Regitine Phenoxybenzamine Serpasol Rescinnamine Diuril Harmonyl Naturetin Hydrochlorothiazide Hydrocortamate Fastin Ismel
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,821,928 B2 Hemmingsen Et Al
    US008821928B2 (12) United States Patent (10) Patent No.: US 8,821,928 B2 Hemmingsen et al. (45) Date of Patent: Sep. 2, 2014 (54) CONTROLLED RELEASE 5,869,097 A 2/1999 Wong et al. PHARMACEUTICAL COMPOSITIONS FOR 6,103,261 A 8, 2000 Chasin et al. 2003.01.18641 A1 6/2003 Maloney et al. PROLONGED EFFECT 2003/O133976 A1* 7/2003 Pather et al. .................. 424/466 2004/O151772 A1 8/2004 Andersen et al. (75) Inventors: Pernille Hoyrup Hemmingsen, 2005.0053655 A1 3/2005 Yang et al. Bagsvaerd (DK); Anders Vagno 2005/O158382 A1* 7/2005 Cruz et al. .................... 424/468 2006, O1939 12 A1 8, 2006 KetSela et al. Pedersen, Virum (DK); Daniel 2007/OOO3617 A1 1/2007 Fischer et al. Bar-Shalom, Kokkedal (DK) 2007,0004797 A1 1/2007 Weyers et al. (73) Assignee: Egalet Ltd., London (GB) 2007. O190142 A1 8, 2007 Breitenbach et al. (Continued) (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 FOREIGN PATENT DOCUMENTS U.S.C. 154(b) by 1052 days. DE 202006O14131 1, 2007 EP O435,726 8, 1991 (21) Appl. No.: 12/602.953 (Continued) (22) PCT Filed: Jun. 4, 2008 OTHER PUBLICATIONS (86). PCT No.: PCT/EP2008/056910 Krogel etal (Pharmaceutical Research, vol. 15, 1998, pp. 474-481).* Notification of Transmittal of the International Search Report and the S371 (c)(1), Written Opinion of the International Searching Authority issued Jul. (2), (4) Date: Jun. 7, 2010 8, 2008 in International Application No. PCT/DK2008/000016. International Preliminary Reporton Patentability issued Jul.
    [Show full text]
  • Imaging Mitochondrial Dynamics in the Adult Heart
    Imaging Mitochondrial Dynamics in the Adult Heart Thesis submitted by Siavash Beikoghli Kalkhoran BSc (First class Hons.), MSc (Distinction) For the degree of Doctor of Philosophy University College London, UK. Institute of Cardiovascular Science The Hatter Cardiovascular Institute, University College London, 67 Chenies Mews, London, WC1E 6HX. October 2017 Declaration I, Siavash Beikoghli Kalkhoran, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. The assistance and contribution of individuals to the generation of results are acknowledged within the methods sections of each chapter. 2 Dedicated to Soheila & Taher 3 Abstract Background Mitochondrial dynamics, the phenomenon which incorporates inter-mitochondrial communication and changes in mitochondrial morphology is central to cellular homeostasis. Although the phenomenon of mitochondrial dynamics has been comprehensively studied under normal and pathological conditions in non-cardiac cells, and more recently in cardiac cell lines, its relevance to adult cardiomyocytes has not been so well-established and is investigated in this thesis. Methods and Results Using 2D and 3D electron microscopy, we initially evaluated the morphological features of the 3 different mitochondrial subpopulations (interfibrillar, peri-nuclear, subsarcolemmal) in adult rodent cardiomyocytes, and demonstrated that they are morphologically unique. These morphological characteristics were found to be altered under pathological conditions such as ischaemia or the genetic ablation of mitochondrial fusion proteins “mitofusins”. Using mice expressing the Dendra2 fluorescence probe, we then confirmed that mitochondrial fusion events (“the inter- mitochondrial communication”) occur in live adult cardiomyocytes, and the fusion rates differ according to the mitochondrial subpopulation.
    [Show full text]
  • Egyptian Drug Guide 2011
    Abimol.Afrin.Betaserc.Daflon.Concor. Epilat.Trio.Epilat.Adalat.Effox.Indral. Maaloxplus.Lipitor.Zolam,Rivo ,D.D.B Panadol.Extra..visineAntiv.VitBBetolv ex.Amaryl.Blokium.Ator.Cidrophage.Egyptian Drug Guide 3rd Edition Avandia.Cardura.Cozaar.DiaBetolvex.2011 Daflon.Hyzaar.Migranil.Reparil.PanadDepartment of Pharmacy Practice and Clinical Pharmacy ol.Mylogin.Voltarin.Telfast.Septriun.S olocortef.Viagra.Tenedene.Tequin.Cla ritine.Epilat.Adalat.Effox.Indral.Maalo xplus.Lipitor.Tavanic.Proximol.Soluco rtef.Visceralgine.Zocor.Tenedone.Clar inase.Dolphen.Novalgin.Colona.Duxil. Eucarbon.Excedrin.Flagyl.Feldene.Di nitra.Anafranil.Comtrex.Librax.Lipost at.Neurobion.Predforte.avandemet.A vendia.Avendemet.Abilaxine.Concor. pon.Tenedone.Clarinase.Dolphen.Col Department of Pharmacy Practice and Clinical Pharmacy Table of Contents DRUGS FOR NEUROLOGIC DISORDERS .................................................................................................................. 5 PAIN MANAGEMENT ........................................................................................................................................... 5 ANALGESIC, ANTI-INFLAMMATORY AND ANTI- PYRETIC DRUGS ............................................................................................. 5 ANALGESIC AND ANTIPYRETICS ...................................................................................................................................... 7 OPIOID ANALGESICS ...................................................................................................................................................
    [Show full text]
  • Down-Regulation of the Expression of Endothelial NO Synthase Is Likely to Contribute to Glucocorticoid-Mediated Hypertension
    Down-regulation of the expression of endothelial NO synthase is likely to contribute to glucocorticoid-mediated hypertension Thomas Wallerath*, Klaus Witte†, Stephan C. Scha¨ fer‡, Petra M. Schwarz*, Winfried Prellwitz§, Paulus Wohlfart¶, Hartmut Kleinert*, Hans-Anton Lehr‡, Bjo¨ rn Lemmer†, and Ulrich Fo¨ rstermann*ʈ Departments of *Pharmacology, ‡Pathology, and §Clinical Chemistry, Johannes Gutenberg University Medical School, 55101 Mainz, Germany; †Institute of Pharmacology and Toxicology, Faculty of Clinical Medicine Mannheim, Ruprecht Karls University Heidelberg, 68169 Mannheim, Germany; and ¶Hoechst Marion Roussel (HMR), Disease Group Cardiovascular Agents, 65926 Frankfurt, Germany Communicated by Ferid Murad, The University of Texas Health Science Center at Houston, Houston, TX, September 7, 1999 (received for review February 9, 1999) Hypertension is a side effect of systemically administered glucocor- (11). There is evidence for the presence of glucocorticoid ticoids, but the underlying molecular mechanism remains poorly receptors on endothelial cells (12) and vascular smooth muscle understood. Ingestion of dexamethasone by rats telemetrically cells (13). Therefore, actions of glucocorticoids on the vascula- instrumented increased blood pressure progressively over 7 days. ture are conceivable. Indeed, effects of glucocorticoids on Plasma concentrations of Na؉ and K؉ and urinary Na؉ and K؉ vascular resistance have been demonstrated and have been excretion remained constant, excluding a mineralocorticoid-medi- explained in part by an increased response of the vasculature to ؊ ؊ ated mechanism. Plasma NO2 ͞NO3 (the oxidation products of catecholamines and angiotensin II (10, 11). NO) decreased to 40%, and the expression of endothelial NO We now demonstrate in vitro and ex vivo that glucocorticoids synthase (NOS III) was found down-regulated in the aorta and down-regulate endothelial NOS III expression by decreasing the several other tissues of glucocorticoid-treated rats.
    [Show full text]